Skip to Content

S 111 (Uribel hyoscyamine 0.12 mg / methenamine 118 mg/methylene blue 10 mg / phenyl salicylate 36 mg / sodium phosphate 40.8 mg)

Generic Name: hyoscyamine/methenamine/methylene blue/phenyl salicylate

Pill with imprint S 111 is Purple, Capsule-shape and has been identified as Uribel hyoscyamine 0.12 mg / methenamine 118 mg/methylene blue 10 mg / phenyl salicylate 36 mg / sodium phosphate 40.8 mg. It is supplied by Mission Pharmacal Company.

Uribel is used in the treatment of urinary tract infection and belongs to the drug class urinary antispasmodics. Risk cannot be ruled out during pregnancy. Uribel hyoscyamine 0.12 mg / methenamine 118 mg/methylene blue 10 mg / phenyl salicylate 36 mg / sodium phosphate 40.8 mg is not a controlled substance under the Controlled Substances Act (CSA).

Images for S 111

Uribel hyoscyamine 0.12 mg / methenamine 118 mg/methylene blue 10 mg / phenyl salicylate 36 mg / sodium phosphate 40.8 mg S 111
Uribel hyoscyamine 0.12 mg / methenamine 118 mg/methylene blue 10 mg / phenyl salicylate 36 mg / sodium phosphate 40.8 mg S 111
Uribel hyoscyamine 0.12 mg / methenamine 118 mg/methylene blue 10 mg / phenyl salicylate 36 mg / sodium phosphate 40.8 mg S 111

Uribel

Generic Name
hyoscyamine/methenamine/methylene blue/phenyl salicylate
Imprint
S 111
Strength
hyoscyamine 0.12 mg / methenamine 118 mg/methylene blue 10 mg / phenyl salicylate 36 mg / sodium phosphate 40.8 mg
Color
Purple
Size
19.00 mm
Shape
Capsule-shape
Availability
Prescription only
Drug Class
Urinary antispasmodics
Pregnancy Category
C - Risk cannot be ruled out
CSA Schedule
Not a controlled drug
Labeler / Supplier
Mission Pharmacal Company
National Drug Code (NDC)
00076-0111
Inactive Ingredients
calcium phosphate dibasic anhydrous, gelatin, magnesium stearate, propylene glycol, shellac, silicon dioxide

Note: Inactive ingredients may vary.

Get help with Imprint Code FAQs.

Related Images for "S 111"

More about Uribel (hyoscyamine / methenamine / methylene blue / phenyl salicylate)

Related treatment guides

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.